Dr. Ivana Barbaric discusses how genetic mutations in hPSCs cultured in vitro confer selective advantages that can affect cell behavior and confound experimental results through the elimination of wild-type cells. Dr. Barbaric is a group leader at the Center for Stem Cell Biology, University of Sheffield, UK.

This presentation and the following Q&A were moderated by Dr. Glyn Stacey from EuroStemCell and Dr. Adam Hirst from STEMCELL Technologies. It was part of the workshop “From hPSCs to Immune Cells”, hosted together with the London Stem Cell Network. During the event, scientists and experts presented on advancements in hPSC culture, the generation of immune cells, and the demands of cell therapy research. Explore the full series here >